or Try an Advanced Search...

    Tumor Necrosis Stocks List

    Symbol Grade Name % Change
    CKPT A Checkpoint Therapeutics, Inc. 2.03
    AMGN C Amgen Inc. -0.29
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Epidermal Growth Factor Receptor Medicine Necrosis Tumor Necrosis Factor Antibodies Biotechnology Blood Cells Bone Bone Disease Cancer Care Cancer Immunotherapy Checkpoint Inhibitor Chemotherapy Clinic Dialysis Dow Jones Component Drugs Growth Factors Healthcare Providers Hematology

    Related ETFs - A few ETFs which own one or more of the above listed Tumor Necrosis stocks.

    Symbol Grade Name Weight
    BBH D Market Vectors Biotech ETF 16.72
    BIS C ProShares UltraShort Nasdaq Biotechnology 8.14
    HRTS D Tema Cardiovascular and Metabolic ETF 7.87
    IBBQ D Invesco Nasdaq Biotechnology ETF 7.87
    IBB C iShares Nasdaq Biotechnology Index Fund 7.84
    View all Tumor Necrosis ETFs...
    Compare ETFs
    Compare BBH to IBBQ Compare BIS to IBB Compare IBBQ to IBB

        Tumor Necrosis Stocks Recent News

        Date Stock Title
        Nov 1 AMGN Amgen Third Quarter 2024 Earnings: EPS Beats Expectations
        Oct 31 AMGN Amgen earns higher revenues in Q3 2024, puts rare diseases in the spotlight
        Oct 31 AMGN Q3 2024 Amgen Inc Earnings Call
        Oct 31 AMGN Amgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFO
        Oct 31 AMGN Amgen Q3 Earnings Beat, Sales In Line, Obesity Candidate in Focus
        Oct 31 AMGN Amgen Inc (AMGN) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic Pipeline ...
        Oct 31 AMGN Amgen Inc. (AMGN) Q3 2024 Earnings Call Transcript
        Oct 31 AMGN Amgen Inc. 2024 Q3 - Results - Earnings Call Presentation
        Oct 31 AMGN Amgen (AMGN) Q3 2024 Earnings Call Transcript
        Oct 30 AMGN Amgen updates 2024 guidance with revenue and EPS ranges including consensus
        Oct 30 AMGN Compared to Estimates, Amgen (AMGN) Q3 Earnings: A Look at Key Metrics
        Oct 30 AMGN Amgen (AMGN) Beats Q3 Earnings Estimates
        Oct 30 AMGN Amgen in charts: Prolia, XGEVA sales gain, while Enbrel continues to wind down in Q3
        Oct 30 AMGN Amgen: Q3 Earnings Snapshot
        Oct 30 AMGN Amgen Non-GAAP EPS of $5.58 beats by $0.47, revenue of $8.5B in-line
        Oct 30 AMGN Amgen posts higher profit, obesity data on track for late this year
        Oct 30 AMGN AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS
        Oct 29 AMGN Amgen Q3 2024 Earnings Preview: All eyes on obesity candidate data
        Oct 29 AMGN Pfizer Unveils Its Next Black Box In Obesity. It's Taking On Amgen.
        Oct 29 AMGN Amgen Inc. (NASDAQ:AMGN) is a favorite amongst institutional investors who own 79%
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Epidermal Growth Factor Receptor Medicine Necrosis Tumor Necrosis Factor Antibodies Biotechnology Blood Cells Bone Bone Disease Cancer Care Cancer Immunotherapy Checkpoint Inhibitor Chemotherapy Clinic Dialysis Dow Jones Component Drugs Growth Factors Healthcare Providers Hematology
        Tumor Necrosis

        Tumor Necrosis is a type of cell death that occurs when cells are exposed to certain stimuli, such as radiation, chemotherapy, or certain drugs. It is a form of programmed cell death that is triggered by the body's own immune system in response to the presence of a tumor. Tumor Necrosis can be beneficial, as it can help to reduce the size of a tumor and prevent it from spreading.

        Browse All Tags